Vivesto ABOASMY 26 EBIT per Share is $-0.02 as of Mar. 2026. GuruFocus rates OASMY with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 811 Drug Manufacturers companies, Vivesto AB ranks better than 91.37% on this metric.
Vivesto AB's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.02.
During the past 3 years, the average EBIT per Share Growth Rate was 57.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 18.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 20.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Vivesto AB's EBIT per Share or its related term are showing as below:
OASMY'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -79.2 Med: 2.1 Max: 57.5
Current: 57.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Vivesto AB was 57.50% per year. The lowest was -79.20% per year. And the median was 2.10% per year.
OASMY's 3-Year EBIT Growth Rate is ranked better than 91.37% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.8
vs OASMY: 57.50
Vivesto AB's EBIT for the
three
months ended in Mar. 2026 was $-0.73 Mil.
Vivesto AB (OTCPK:OASMY) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Vivesto AB EBIT per Share Related Terms
Vivesto AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Vivesto AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivesto AB (OASMY) has a EBIT per Share of $-0.02 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Vivesto AB and its competitors. According to the industry distribution chart, Vivesto AB ranks #70 out of 811 companies in the Drug Manufacturers industry, placing it in the top 8.6%.
Is Vivesto AB's EBIT per Share too high?
Vivesto AB's current EBIT per Share is $-0.02. Based on the distribution chart, Vivesto AB ranks #70 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vivesto AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vivesto AB ranks #70 out of 811 companies for EBIT per Share. This places Vivesto AB in the top 9% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Vivesto AB and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivesto AB's current EBIT per Share is $-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (OASMY) has a current EBIT per Share of $-0.02. The current EBIT per Share is $-0.02. Vivesto AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Vivesto AB (OASMY), the current EBIT per Share is $-0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
26GF Score
Get the complete analysis for OASMY
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OASMY has been successfully added to your 
